Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2009
Published online before print July 2, 2009, doi: 10.1161/CIRCRESAHA.109.202440
A more recent version of this article appeared on July 31, 2009
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
105/3/219    most recent
CIRCRESAHA.109.202440v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Marston, S.
Right arrow Articles by Watkins, H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marston, S.
Right arrow Articles by Watkins, H.
Related Collections
Right arrow Contractile function
Right arrow Hypertrophy
Right arrow Myocardial cardiomyopathy disease

Submitted on April 2, 2009
Revised on June 23, 2009
Accepted on June 24, 2009

Evidence From Human Myectomy Samples That MYBPC3 Mutations Cause Hypertrophic Cardiomyopathy Through Haploinsufficiency

Steven Marston ; O'Neal Copeland ; Adam Jacques ; Karen Livesey ; Victor Tsang ; William J. McKenna ; Shapour Jalilzadeh ; Sebastian Carballo ; Charles Redwood ; and Hugh Watkins *

From Cardiovascular Science (S.M., O.C., A.J.), National Heart and Lung Institute, Imperial College London; Department of Clinical Genetics (K.L.), Churchill Hospital, Oxford; Institute of Cardiovascular Science (V.T., W.J.M.), University College, London; Department of Cardiovascular Medicine (S.J., S.C., C.R., H.W.), University of Oxford, UK.

* To whom correspondence should be addressed. E-mail: hugh.watkins{at}cardiov.ox.ac.uk.

Most sarcomere gene mutations that cause hypertrophic cardiomyopathy are missense alleles that encode dominant negative proteins. The potential exceptions are mutations in the MYBPC3 gene (encoding cardiac myosin-binding protein [MyBP]-C), which frequently encode truncated proteins. We sought to determine whether there was evidence of haploinsufficiency in hypertrophic cardiomyopathy caused by MYBPC3 mutations by comparing left ventricular muscle from patients undergoing surgical myectomy with samples from donor hearts. MyBP-C protein and mRNA levels were quantitated using immunoblotting and RT-PCR. Nine of 37 myectomy samples had mutations in MYBPC3: 2 missense alleles (Glu258Lys, Arg502Trp) and 7 premature terminations. No specific truncated MyBP-C peptides were detected in whole muscle homogenates of hypertrophic cardiomyopathy tissue. However, the overall level of MyBP-C in myofibrils was significantly reduced (P<0.0005) in tissue containing either a truncation or missense MyBP-C mutation: 0.76±0.03 compared with 1.00±0.05 in donor and 1.01±0.06 in non-MYBPC3 mutant myectomies. The absence of any detectable truncated MyBP-C argues against its incorporation in the myofiber and any dominant negative effect. In contrast, the lowered relative level of full length protein in both truncation and missense MYBPC3 mutations argues strongly that haploinsufficiency is sufficient to cause the disease.


Key words: cardiomyopathy • mutation • myocardial contractility